Cardiometabolic risk factors in different clinicomorphological stages of non-alcoholic fatty liver disease in patients with abdominal obesity
https://doi.org/10.14341/2071-8713-4968
Abstract
The aim of the study was to compare clinical, laboratory and morphological parameters in patients with abdominal obesity and non-alcoholic fatty liver disease (NAFLD), and assessing the relationship between the degree of severity, stage NAFLD and cardiometabolic risk factors for type 2 diabetes mellitus and cardiovascular disease. The present study examined the content of adiponectin and rates of glucose and lipid metabolism in obese patients at different stages of NAFLD. According to the study, morphologically NAFLD was confirmed in 95.2% of patients. NAFLD was associated with various cardiometabolic disorders (dyslipidemia, disorders of glucose metabolism and insulin resistance), growing in frequency and severity with the progression NAFLD; and low levels of adiponectin decreasing with a deterioration NAFLD.
About the Authors
K Komshilovanauchnyy sotrudnik otdeleniya terapii s gruppoy ozhireniya
E Troshina
professor, d.m.n., zav. otdeleniem terapii s gruppoy ozhireniya
S Butrova
k.m.n., vedushchiy nauchnyy sotrudnik otdeleniya terapii s gruppoy ozhireniya
P Bogomolov
zav. gepatologicheskim otdeleniem Moskovskogo oblastnogo gepatologicheskogo tsentra pri nauchno-issledovatel'skom klinicheskom institute (MONIKI) im. M.F. Vladimirskogo.
A Knyazeva
vedushchiy nauchnyy sotrudnik laboratorii klinicheskoy biokhimii
References
1. Ивашкин В.Т., Драпкина О.М., Шульпекова Ю.О. Диагностика и лечение неалкогольной жировой болезни печени. Методические рекомендации. М.: ООО «Издательский дом М-Вести», 2009.
2. Никитин И.Г. Скрининговая программа по выявлению распространенности неалкогольной жировой болезни печени и определению факторов риска развития заболевания. Российские Медицинские Вести 2010;XV(1):41–6.
3. Павлов Ч.С., Ивашкин В.Т. Биопсия печени: методология и практика сегодня. Российский журнал гастроэнтерологии, гепатологии, колопроктологии 2006;XVI(4):65–78.
4. Browning J., Szczepaniak L., Dobbins R., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004;40:1387–95.
5. Bugianesi E., Gastaldelli A., Vanni E., Gambino R., Cassader M., Baldi S., Ponti V., Pagano G., Ferrannini E., Rizzetto M. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 2005;48:634–42.
6. Cnop M., Havel P., Utzschneider K. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasms lipoproteins: evidence for independent roles of age and sex. Diabetologia 2003;46:459–69.
7. Dowman J.K., Tomlinson J.W., Newsome P.N. Pathogenesis of non-alcoholic fatty liver disease. QJM: 2010;103(2):71–83.
8. Fassio E., Alvarez E., Dominguez N. Natural history of non-alcoholic steatohepatitis: a longitudinal study of liver biopsies. Hepatology 2004;40:820–6.
9. Kleiner D.E., Brunt E.M., Van Natta M., Behling C., Contos M.J., Cummings O.W., Ferrell L.D., Liu Y.C., Torbenson M.S., Unalp-Arida A., Yeh M., McCullough A.J., Sanyal A.J. Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005 Jun;41(6):1313–21.
10. Lazo M., Clark J. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis 2008;28(4):339–50.
11. Marchesini G., Brizi M., Morselli-Labate A., Bianchi G., Bugianesi E., McCullough A., Forlani G., Melchionda N. Association of nonalcoholic fatty liver disease with insulin resistance. Am. J. Med 1999;107(5):450–5.
12. Mazhar S., Shiehmorteza M., Sirlin C. Noninvasive assessment of hepatic steatosis. Clin Gastroenterol Hepatol 2009;7(2):135–40.
13. Milner K., Van der Poorten D., Xu A., Bugianesi E., Kench J., Lam K., Chisholm D., George J. Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver disease. Hepatology 2009;49(6):1926–34.
14. Mofrad P., Contos M., Haque M. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003;37:1286–92.
15. Musso G., Gambino R., Cassader M. Non-alcoholic fatty liver disease from pathogenesis to management: an update. Obesity Reviews 2010;11(6):430–45.
16. Schwenzer N., Springer F., Schraml C., Stefan N., Machann J., Schick F. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol 2009;51(3):433–45.
17. Stefan N., Kantartzis K., Häring H. Causes and Metabolic Consequences of Fatty Liver. Endocrine Reviews 2008;29(7):939–60.
18. Tilg H., Diehl A., Li Z., Lin H., Yang S. Cytokines and the pathogenesis of non-alcoholic steatohepatitis. Gut 2005;54:303–6.
19. Tobari M., Hashimoto E. Imaging of nonalcoholic steatohepatitis: advantages and pitfalls of ultrasonography and computed tomography. Intern Med 2009;48(10):739–46.
Review
For citations:
, , , , Cardiometabolic risk factors in different clinicomorphological stages of non-alcoholic fatty liver disease in patients with abdominal obesity. Obesity and metabolism. 2012;9(3):20-25. (In Russ.) https://doi.org/10.14341/2071-8713-4968
Views:
521
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
